Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 1/2012

01-02-2012 | ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies

Authors: Jeffrey S. Dlott, Robert A. S. Roubey

Published in: Current Rheumatology Reports | Issue 1/2012

Login to get access

Abstract

Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, and/or IgA) which interfere with one or more of phospholipid-dependent in vitro coagulation tests, eg, activated partial thromboplastin time (aPTT), kaolin clotting time (KCT), dilute Russell viper venom time (dRVVT), and dilute prothrombin time (dPT). LAs may be seen in a variety of clinical settings including the primary antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), other autoimmune diseases, secondary to infections, malignancies, and in association with certain drugs. LAs associated with the antiphospholipid syndrome and other autoimmune disease recognize certain phospholipid-binding proteins (β2-glycoprotein I [β2GPI] or prothrombin). Many drugs have been implicated as possibly causing LAs, although the majority of such cases are limited to a select few. Drug-induced LAs are heterogeneous, differing in laboratory findings as well as related clinical complications. This paper reviews the English medical literature on drug-induced LA and potential mechanisms of induction.
Literature
1.
Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–2.
2.
3.
Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis. 1974;3:65–93.PubMed
4.
Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963;62:416–30.PubMed
5.
Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb. 1972;1:75–95.
6.
Schroeder HA, Morrow JD, Perry Jr HM. Studies on the control of hypertension by hyphex. I. Effects on blood pressure. Circulation. 1953;8(5):672–80.PubMed
7.
Lindqvist TT. Lupus erythematosus disseminatus after administration of mesantoin; report of two cases. Acta Med Scand. 1957;158(2):131–8.PubMedCrossRef
8.
9.
10.
Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976;48(4):499–509.PubMed
11.
Bell WR, Boss GR, Wolfson JS. Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med. 1977;137(10):1471–3.PubMedCrossRef
12.
Davis S, Furie BC, Griffin JH, Furie B, Willey R. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. Am J Hematol. 1978;4(4):401–7.PubMedCrossRef
13.
Galanakis DK, Newman J, Summers D. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. JAMA. 1978;239(18):1873–4.PubMedCrossRef
14.
Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92:156–9.PubMed
15.
Edwards RL, Rick ME, Wakem CJ. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus. Arch Intern Med. 1981;141(12):1688–90.PubMedCrossRef
16.
Sanfelippo MJ, Drayna CJ. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol. 1982;77:275–9.PubMed
17.
O’Brien DC, Shimomura SK. Procainamide and the lupus anticoagulant. Drug Intell Clin Pharm. 1984;18:971.
18.
Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. 1985;19:265–75.PubMedCrossRef
19.
Day HJ, Cherrey R, O'Hara D, Carebello J. Incidence of procainamide-induced anticoagulant. Thromb Haemost. 1987;58:394. Ref Type: Abstract.
20.
Weber MT, Hocking WG. Procainamide induced lupus anticoagulant. Wis Med J. 1988;87(9):30–2.PubMed
21.
Heyman MR, Flores RH, Edelman BB, Carliner NH. Procainamide-induced lupus anticoagulant. South Med J. 1988;81(7):934–6.PubMedCrossRef
22.
Li GC, Greenberg CS, Currie MS. Procainamide-induced lupus anticoagulants and thrombosis. South Med J. 1988;81(2):262–4.PubMedCrossRef
23.
Schlesinger PA, Peterson LA. Procainamide-associated lupus anticoagulants and thrombotic events. Arthritis Rheum. 1988;31:S54. Ref Type: Abstract.
24.
Asherson RA, Zulman J, Hughes GR. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis. 1989;48:232–5.PubMedCrossRef
25.
Kushner M, Simonian N. Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. Stroke. 1989;20:225–9.PubMedCrossRef
26.
List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematol. 1989;82(1):50–2.PubMedCrossRef
27.
Humphries JE. Persistent procainamide-associated lupus anticoagulant. Clin Hemost Rev. 1996;10:13.
28.
Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997;24(6):1083–8.PubMed
29.
Freeman NJ, Fajardo L, Carvalho A. Simultaneous procainamide-induced immune thrombocytopenia and lupus anticoagulant. Am J Hematol. 1995;48(2):133–4.PubMed
30.
Kameda H, Mimori T, Kaburaki J, Fujii T, Takahashi T, Akaishi M, et al. Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. 1998;37(11):1236–9.PubMedCrossRef
31.
Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. 1988;259:550–4.PubMedCrossRef
32.
Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res. 1988;51:267–81.PubMedCrossRef
33.
Clyne LP, Farber LR, Chopyk RL. Procainamide-induced circulating anticoagulants in a congenitally-deficient factor XI patient. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(2):239–44.PubMed
34.
Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983;79(6):678–82.PubMed
35.
Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH. Antinuclear antibody induced by procainamide. A prospective study. N Engl J Med. 1969;281(2):64–6.PubMedCrossRef
36.
Bird MR, O’Neill AI, Buchanan RR, Ibrahim KM, Des PJ. Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage. Pathology. 1995;27(2):136–9.PubMedCrossRef
37.
Lavie CJ, Biundo J, Quinet RJ, Waxman J. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med. 1985;145(3):446–8.PubMedCrossRef
38.
39.
Canoso RT, Hutton RA, Deykin D. A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol. 1977;2(2):183–91.PubMedCrossRef
40.
Zucker S, Zarrabi MH, Romano GS, Miller F. IgM inhibitors of the contact activation phase of coagulation in chlorpromazine-treated patients. Br J Haematol. 1978;40(3):447–57.PubMedCrossRef
41.
Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979;91(2):194–9.PubMed
42.
Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982;13(2):121–9.PubMedCrossRef
43.
Tollefson G, Rodysill K, Cusulos M. A circulating lupus-like coagulation inhibitor induced by chlorpromazine. J Clin Psychopharmacol. 1984;4(1):49–51.PubMedCrossRef
44.
Pavlidakey GP, Hashimoto K, Heller GL, Daneshvar S. Chlorpromazine-induced lupuslike disease. Case report and review of the literature. J Am Acad Dermatol. 1985;13(1):109–15.PubMedCrossRef
45.
Zengotita HE, Holt RJ. Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect. J Clin Psychiatry. 1986;47(1):35–7.PubMed
46.
Canoso RT, De Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27:272–5.PubMedCrossRef
47.
Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum. 1988;31(7):923–6.PubMedCrossRef
48.
el-Mallakh RS, Donaldson JO, Kranzler HR, Racy A. Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics. 1988;29(1):109–13.PubMedCrossRef
49.
Jude B, Goudemand J, Dolle I, Caron C, Watel A, Tiry C, et al. Lupus anticoagulant: a clinical and laboratory study of 100 cases. Clin Lab Haematol. 1988;10:41–51.PubMed
50.
Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. 1990;93:771–5.PubMed
51.
Kaslow KA, Rosse RB, Zeller JA, Nagy MS, Deustch SI. Phenothiazine-induced lupus anticoagulant. J Clin Psychiatry. 1992;53(3):103–4.PubMed
52.
Morgan M, Chesterman CN, Downs K, Biggs JC. Clinical analysis of 125 patients with the lupus anticoagulant. Aust N Z J Med. 1993;23:151–6.PubMedCrossRef
53.
Gharavi AE, Sammaritano LR, Wen J, Miyawaki N, Morse JH, Zarrabi MH, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: Effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21:94–9.PubMed
54.
Tribout B, Gosset O, Fuentes V, Gross S, Fardelonne P, Lernout P, et al. High prevalence of antiphospholipid antibodies without increased risk of thrombosis in psychiatric patients treated chronically with neuroleptic drugs. Nouv Rev Fr Hematol. 1995;37:S79–82.
55.
Matsukawa Y, Satoh M, Itoh T, Nishinarita S, Horie T, Abe K, et al. Plasmapheresis for a schizophrenic patient with drug-induced lupus anti-coagulant. J Int Med Res. 1996;24(1):147–50.PubMed
56.
Goldman LS, Hudson JI, Weddington Jr WW. Lupus-like illness associated with chlorpromazine. Am J Psychiatry. 1980;137(12):1613–4.PubMed
57.
Dubois EL, Tallman E, Wonka RA. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA. 1972;221(6):595–6.PubMedCrossRef
58.
Berglund S, Gottfries CG, Gottfries I, Stormby K. Chlorpromazine-induced antinuclear factors. Acta Med Scand. 1970;187(1–2):67–74.PubMed
59.
Canoso RT, Romero JA, Yunis EJ. Immunogenetic markers in chlorpromazine-induced tardive dyskinesia. J Neuroimmunol. 1986;12(3):247–52.PubMedCrossRef
60.
Kahn G, Davis BP. In vitro studies on longwave ultraviolet light-dependent reactions of the skin photosensitizer chlorpromazine with nucleic acids, purines and pyrimidines. J Invest Dermatol. 1970;55(1):47–52.PubMedCrossRef
61.
Kanjolia A, Valigorsky JM, Joson-Pasion ML. Clozaril-induced lupus anticoagulant. Am J Hematol. 1997;54(4):345–6.PubMedCrossRef
62.
Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol. 1972;12(1):39–47.PubMed
63.
Beernink DH, Miller III JJ. Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Pediatr. 1973;82(1):113–7.PubMedCrossRef
64.
Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics. 1976;57(4):529–34.PubMed
65.
Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol. 1993;16(1):19–29.PubMedCrossRef
66.
Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med. 1987;111:719–22.PubMed
67.
Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer. 1994;73(6):1621–4.PubMedCrossRef
68.
Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21(2):350–2.PubMed
69.
Ferraccioli G, Mecchia F, Di PE, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002;61(4):358–61.PubMedCrossRef
70.
Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–43.PubMedCrossRef
71.
Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2840–4.PubMedCrossRef
72.
Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979–84.PubMedCrossRef
73.
Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Reports. 2010;4:12.PubMedCrossRef
74.
Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol. 2007;17(6):546–7.PubMed
75.
Vereckei E, Krivan G, Reti M, Szodoray P, Poor G, Kiss E. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol. 2010;39(2):175–7.PubMedCrossRef
76.
Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847–61.PubMedCrossRef
77.
Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis Jr JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620–6.PubMed
78.
Sebastian JK, Voetsch B, Stone JH, Romay-Penabad Z, Lo GH, Allen NB, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener’s granulomatosis with and without history of a thrombotic event. J Rheumatol. 2007;34(12):2446–50.PubMed
79.
Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1831–4.PubMedCrossRef
80.
81.
Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338–47.PubMedCrossRef
82.
Orris DJ, Lewis JH, Spero JA, Hasiba U. Blocking coagulation inhibitors in children taking penicillin. J Pediatr. 1980;97(3):426–9.PubMedCrossRef
83.
Brodeur GM, O’Neill PJ, Willimas JA. Acquired inhibitors of coagulation in nonhemophiliac children. J Pediatr. 1980;96(3 Pt 1):439–41.PubMed
84.
85.
Alarcon-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc. 1969;44(9):664–81.PubMed
86.
Sheng Y, Kandiah DA, Krilis SA. Anti-b2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to b2-glycoprotein I with low affinity: dimerization of b2-glycoprotein I induces a significant increase in anti-b2-glycoprotein I antibody affinity. J Immunol. 1998;161(4):2038–43.PubMed
87.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990;87:4120–4.PubMedCrossRef
88.
Uchman B, Triplett DA. Inhibitor effect of polymyxin B on the X-ase and prothrombinase complex formation. Thromb Haemost. 1989;62:375. Ref Type: Abstract.
89.
Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74(6):1597–603.PubMed
90.
Cajal Y, Ghanta J, Easwaran K, Surolia A, Jain MK. Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts. Biochemistry. 1996;35(18):5684–95.PubMedCrossRef
91.
Packman CH, Leddy JP. Drug-related immune hemolytic anemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Hematology. New York: McGraw-Hill; 1995. p. 691–7.
92.
Kornberg A, Silber L, Yona R, Kaufman S. Clinical manifestations and laboratory findings in patients with lupus anticoagulants. Eur J Haematol. 1989;42:90–5.PubMedCrossRef
93.
Sanmarco M, Soler C, Christides C, Raoult D, Weiller PJ, Gerolami V, et al. Prevalence and clinical significance of IgG isotype anti-beta-2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129(5):499–506.PubMedCrossRef
Metadata
Title
Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies
Authors
Jeffrey S. Dlott
Robert A. S. Roubey
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0227-1

Other articles of this Issue 1/2012

Current Rheumatology Reports 1/2012 Go to the issue

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Laboratory Diagnosis of the Lupus Anticoagulant

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Cognitive Dysfunction and Antiphospholipid Antibodies

SCLERODERMA (J VARGA, SECTION EDITOR)

Dendritic Cells: Novel Players in Fibrosis and Scleroderma

SCLERODERMA (J VARGA, SECTION EDITOR)

An Update on the Evaluation and Management of Pulmonary Hypertension in Scleroderma

SCLERODERMA (J VARGA, SECTION EDITOR)

Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and Management

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Management of Obstetric Antiphospholipid Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits